“We are thrilled to welcome David to the Sixfold Team” said Dr. George Foot, founder and co-CEO of Sixfold Bioscience. “David joins the team with significant experience at both early and late stage biotech companies and is providing strategic guidance as we look to scale-up across several functions of the company” 

David has previously occupied several senior finance roles within both US and UK privately and publicly owned life-science companies, most recently as CFO at Juvenescence.  Prior to that he was CFO at then AIM-listed Silence Therapeutics, a gene-silencing RNA medicines company. From 2010-2016 he was Regional CFO for EUMEA at BioMarin, a NASDAQ gene discovery company. 

“Sixfold has made several breakthroughs in oligonucleotide delivery that have built real value in the company. Working with Anna, George, Tina and the dynamic Sixfold team is a tremendous opportunity” said David Ellam

Sixfold Biosciences is a biotechnology company solving one of the most critical challenges preventing the greater utilization of powerful RNA medicines: delivery. Sixfold’s solution takes evolution as inspiration, learning and mimicking how RNA is naturally delivered to different cell types in the body. Using advanced AI and Bayesian Optimization, Sixfold is learning the language that encodes RNA-shuttle interactions and destination selection, unlocking new cell types for treatment.